Skip to content
Telehealth Graded

Search Telehealth Graded

Use arrow keys or Tab to browse. Enter opens a result. Escape closes search.

Enter a name or topic to search.

State guide

Compounded GLP-1s in Ohio

Most of this site is about what things cost. This page is about what a pharmacy in Ohio is allowed to make. The state's Board of Pharmacy put dates on when compounding semaglutide and tirzepatide had to stop, and named two peptides that were never allowed in the first place.

Every source on this page was read first-hand in September 2026, and each one below carries the date printed on the document itself.

1
document cited
4
sourced facts
1
primary source

What changed, and what the document says

  1. What the guidance is

    Context

    Not a new rule. The board is restating law that already applied, which is why it has dates attached rather than a comment period.

    “This guidance highlights existing law and is intended for the benefit of practitioners and the public to promote better understanding of the laws governing the compounding and sale of GLP-1 drugs.”

    The Ohio Board of Pharmacy — Date Issued: 7/17/2025

  2. Salt forms

    Not covered

    The semaglutide sodium and semaglutide acetate you see advertised are not the ingredient in the approved drugs, and the board says so directly.

    “Ozempic®, Wegovy®, and Rybelsus® contain semaglutide base – not a salt form. Mounjaro® and Zepbound® contain tirzepatide base – not a salt form. Therefore, only the base is a component of an FDA-approved human drug product. The salt forms are different active ingredients than those used in FDA-approved drugs, and do not meet FD&C Act requirements for compounding.”

    The Ohio Board of Pharmacy — Date Issued: 7/17/2025

  3. Retatrutide and cagrilintide

    Not covered

    Not a timing question. These two cannot be compounded, and existing stock had to go.

    “Retatrutide and/or Cagrilintide cannot be used in compounding under federal and state law.”

    The Ohio Board of Pharmacy — Date Issued: 7/17/2025

  4. What happens to inventory

    Conditions apply

    Immediate disposal, not sell-through.

    “This does not apply to retatrutide or cagrilintide as these drugs are NOT FDA-approved. All inventory containing retatrutide or cagrilintide must be disposed of immediately.”

    The Ohio Board of Pharmacy — Date Issued: 7/17/2025

Telehealth in Ohio

Some providers pay us a commission when you sign up through our links, at no extra cost to you.

Which of these companies serve Ohio?

Of the 284 companies we grade, 28 publish a list of the states they are licensed in. We checked 250 more and found no such list on any page we read; 6 we have not checked either way.

21 of those lists name Ohio: Gala Health, Care Bare Rx, Vita Bella, TelePeptide, Levity, Wisp, WePeptideRx, Ways2Well, TeleClinic, Tyde Wellness, Willow, VevaRx, Trimi, Enhance MD, HumeCare+, Rx.com, Mojoon, Peak Wellness, Sprout Health, Allara Health, and MEDvidi. That is a licensure claim each company makes about itself, not something we checked with a state board.

A published list is a starting point, not a guarantee. If availability decides your choice, ask before you pay and get the answer in writing.

Coverage decides what you pay before cash does. See how state Medicaid programs cover GLP-1s and what a prior-authorization denial turns on.

Sources

Each document below was fetched and read on the date shown beside it, which is the date printed on the document — not always the date in its web address. All of them were read in September 2026.

Nothing on this page is medical advice, and nobody here is a clinician. Coverage rules change; check the linked document before you rely on it.